By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CytoDyn 

5 Centerpointe Drive
Suite 400
Lake Oswego  Oregon  97035  U.S.A.
Phone: 971-204-0382 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
CytoDyn Announces Investment Community Call To Discuss Interim Results From Its Treatment Substitution Study In Patients With HIV 7/31/2014 8:59:56 AM
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014 6:56:44 AM
CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy 5/15/2014 11:38:21 AM
CytoDyn Announces First HIV Patient Dosing With PRO 140 In Phase 2b Clinical Trial For Treatment Substitution Protocol 5/14/2014 11:45:54 AM
CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy 3/19/2014 9:06:58 AM
CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy 3/19/2014 7:26:51 AM
CytoDyn Submits Protocol To FDA For Phase 2b Clinical Study Of PRO 140 For Treatment Substitution In Patients With HIV 2/18/2014 9:59:10 AM
CytoDyn Appoints Denis R. Burger, Ph.D. To Board Of Directors 2/13/2014 10:04:17 AM
CytoDyn To Present At 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference On Monday, February 10, 2014 At 10:00 AM Eastern 2/5/2014 7:53:20 AM
CytoDyn Signs Agreement With Amarex Clinical Research LLC To Prepare Two Phase 2b Clinical Trial Protocols To Explore Two Additional Therapeutic Indications For PRO 140 1/28/2014 9:41:54 AM
12345678910...
//-->